AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1679446 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated bar soap
Number of subjects: 0
Study 6223819 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive medroxyprogesterone acetate (MPA)
Number of subjects: 83
Study 6223819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 29286983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEx)
Number of subjects: 0
Study 29286983 — intervention group
Group type: COMPARATOR
Intervention: Stretching and Toning (ST)
Number of subjects: 0
Study 28597981 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Child (patient perspective)
Number of subjects: 0
Study 28597981 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Treatment (interviewer perspective)
Number of subjects: 0
Study 28597981 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 0
Study 27402021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 12.5%)
Number of subjects: 30
Study 27402021 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FiO2 20.0%)
Number of subjects: 30
Study 24091759 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis with additional balloon dilatation
Number of subjects: 386
Study 24091759 — intervention group
Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis alone (control group)
Number of subjects: 386
Study 22327497 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa-IPV
Number of subjects: 305
Study 22327497 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV
Number of subjects: 305
Study 20873894 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC (telephone continuing care with counseling)
Number of subjects: 252
Study 20873894 — intervention group
Group type: EXPERIMENTAL
Intervention: TM (telephone continuing care with monitoring and feedback)
Number of subjects: 252
Study 20873894 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 252
Study 17584319 — intervention group
Group type: EXPERIMENTAL
Intervention: Local PUVA paint
Number of subjects: 25
Study 17584319 — intervention group
Group type: COMPARATOR
Intervention: Local narrowband UVB (NB-UVB) phototherapy
Number of subjects: 25
Study 15983278 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing contingent on drug abstinence (ACH)
Number of subjects: 196
Study 15983278 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing not contingent on abstinence (NACH)
Number of subjects: 196
Study 15983278 — intervention group
Group type: COMPARATOR
Intervention: No housing (NH)
Number of subjects: 196
Study 15983278 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ACH, NACH, NH)
Number of subjects: 196
Study 12428312 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg p.o.)
Number of subjects: 117
Study 12428312 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.05 mg.kg‐1 i.m.)
Number of subjects: 117
Study 12428312 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (2 h before operation)
Number of subjects: 117
Study 12428312 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1 h before operation)
Number of subjects: 117
Study 9467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (10 micrograms/kg) administered as a 30-second intravenous bolus infusion
Number of subjects: 623
Study 9467047 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (32 mg) administered as a 15-minute intravenous infusion
Number of subjects: 623
Study 8582214 — intervention group
Group type: EXPERIMENTAL
Intervention: Local arterial infusion of 5-FU
Number of subjects: 19
Study 8582214 — intervention group
Group type: COMPARATOR
Intervention: Control group (68 patients)
Number of subjects: 19
Study 2784824 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 16
Study 2784824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (10 mg)
Number of subjects: 16
Study 2784824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 322817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin (250 mg six-hourly for four days)
Number of subjects: 34
Study 322817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study 31738574 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) during surgery
Number of subjects: 40
Study 31738574 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SSC after surgery)
Number of subjects: 40
Study 29061194 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Scout Intervention (community health workers using motivational interviewing and mobile health tools)
Number of subjects: 2600
Study 29061194 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2600
Study 29061194 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Scout Intervention
Number of subjects: 2600
Study 27136906 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 41
Study 27136906 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 41
Study 27136906 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 20 mg
Number of subjects: 41
Study 27136906 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg (twice daily for 14 days)
Number of subjects: 41
Study 27136906 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK198602
Number of subjects: 41
Study 27136906 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41
Study 23665155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training evaluation and feedback (EF group)
Number of subjects: 330
Study 23665155 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 330
Study 22610801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (1000 micrograms)
Number of subjects: 200
Study 22610801 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 units)
Number of subjects: 200
Study 22610801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol
Number of subjects: 200
Study 22610801 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin
Number of subjects: 200
Study 19702597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg/day (n=9)
Number of subjects: 18
Study 19702597 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day (n=9)
Number of subjects: 18
Study 19702597 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=9)
Number of subjects: 18
Study 17352093 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts of smear-positive TB patients
Number of subjects: 246845
Study 17352093 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacts of smear-negative TB patients
Number of subjects: 246845
Study 17352093 — intervention group
Group type: COMPARATOR
Intervention: Non-contacts (no TB case at home)
Number of subjects: 246845
Study 17352093 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts with a TB case
Number of subjects: 246845
Study 16153354 — intervention group
Group type: EXPERIMENTAL
Intervention: CMHN problem-solving treatment
Number of subjects: 247
Study 16153354 — intervention group
Group type: EXPERIMENTAL
Intervention: generic CMHN treatment
Number of subjects: 247
Study 16153354 — intervention group
Group type: COMPARATOR
Intervention: usual GP care
Number of subjects: 247
Study 11964744 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 11964744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids
Number of subjects: 0
Study 9456242 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHA-based regimen
Number of subjects: 19
Study 9456242 — intervention group
Group type: COMPARATOR
Intervention: Expert outlining method
Number of subjects: 19
Study 9456242 — intervention group
Group type: COMPARATOR
Intervention: Computer-based threshold method
Number of subjects: 19
Study 8593925 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.5 mg X 3/d)
Number of subjects: 216
Study 8593925 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Treatment (TCT)
Number of subjects: 216
Study 8593925 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide + TCT
Number of subjects: 216
Study 8593925 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 216
Study 2714050 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 110
Study 2714050 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine
Number of subjects: 110
Study 2714050 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and Antipyrine
Number of subjects: 110
Study 1100179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment after craniospinal irradiation
Number of subjects: 0
Study 1100179 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who relapsed
Number of subjects: 0
Study 31600269 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance care (prescheduled care)
Number of subjects: 252
Study 31600269 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided care (control intervention)
Number of subjects: 252
Study 28446548 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with surgical ventricular reconstruction (SVR)
Number of subjects: 1000
Study 28446548 — intervention group
Group type: COMPARATOR
Intervention: CABG without surgical ventricular reconstruction (SVR)
Number of subjects: 1000
Study 28446548 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with or without SVR
Number of subjects: 1000
Study 25924029 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotically assisted minimally invasive bypass surgery
Number of subjects: 70
Study 25924029 — intervention group
Group type: COMPARATOR
Intervention: Conventional bypass surgery
Number of subjects: 70
Study 24091311 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine (Cervarix®; GlaxoSmithKline Vaccines)
Number of subjects: 120
Study 24091311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Al[OH]3)
Number of subjects: 120
Study 21623467 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 10% of basal caloric intake
Number of subjects: 46
Study 21623467 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 30% of basal caloric intake
Number of subjects: 46
Study 21623467 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) at 10% or 30% of basal caloric intake
Number of subjects: 46
Study 19329361 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 2143
Study 19329361 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 2143
Study 19329361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2143
Study 15188794 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance oral nifedipine therapy (n=37) administered 20 mg every six hours
Number of subjects: 73
Study 15188794 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls, n=36)
Number of subjects: 73
Study 15188794 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance oral nifedipine therapy (n=37)
Number of subjects: 73
Study 10928373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 170
Study 10928373 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 170
Study 10928373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (Salmonella diarrhea)
Number of subjects: 170